Jeff Hoschander is a partner in the firm’s Litigation practice. Jeff’s experience is broad, with a primary focus on the representation of corporations in complex commercial, life sciences, and securities litigation, as well as regulatory enforcement matters. Jeff frequently represents global leaders in the financial industry in high-stakes litigation and enforcement actions. With a distinct perspective attributable to having earned a medical degree, Jeff also specializes in advising clients in the pharmaceutical, biotech and medical device industries on litigation, regulatory and transaction-related matters.

• Representing several defendants in securities class actions related to the cannabis industry
• Representing a pharmaceutical company in a securities class action involving allegations of antitrust violations in connection with the marketing of pharmaceuticals
• Representing a large financial institution in several mortgage-backed securities cases
• Representing the underwriters in securities litigation related to the IPO of a bioelectronic medicine company
• Obtained dismissal for an underwriter in a securities class action arising from an offering by a pharmaceutical company involving allegations regarding disclosures of clinical trial results
• Obtained dismissal for underwriters in a securities class action arising from an offering by Insmed Incorporated involving allegations of misrepresentations regarding the regulatory approval prospects for a drug candidate
• Obtained dismissal for underwriters in a securities class action arising out of an offering by issuer China Mobile Games & Entertainment Group Limited
• Represented directors/officers of a multinational foreign financial institution in connection with a shareholder derivative litigation in which the plaintiff voluntarily dismissed the case while the motion to dismiss was pending
• Obtained dismissals for a regional bank in a federal securities fraud class action
• Represented several corporations in various investigations by the U.S. Department of Justice, U.S. Securities Exchange Commission and other government agencies
• Represented Countrywide in connection with mortgage-backed securities litigation matters
• Represented the Securities Industry and Financial Markets Association (SIFMA) as amicus curiae in a securities litigation matter
• Represented Bank of America in connection with several securities litigation matters
• Represented multinational foreign corporation in connection with cross-border discovery matters
• Represented multinational foreign financial institution in connection with investigations and settlement of claims regarding cross-border banking/tax issues by the U.S. Department of Justice, U.S. Securities Exchange Commission and U.S. Internal Revenue Service

Publications

• Author, “Eighth Circuit Affirms Dismissal of Merger-Related Derivative Suit for Failure to Plead Demand Excusal,” The M&A Lawyer, May 2022
• Author, “Delaware Court of Chancery Rejects Motion to Stay SPAC Breach of Fiduciary Duty Suit Pending Parallel Federal Securities Action,” The M&A Lawyer, April 2022 
• Co-author, “Delaware Supreme Court Overrules Gentile Carve-out, Holding an Improper Transfer of Economic Value & Voting Power to a Controlling Stockholder Through an Equity Overpayment is a Derivative Claim,” Thomson Reuters, December 2021
• Co-author, “New York Appellate Court Holds That Claims for Breach of RMBS Representations and Warranties Accrue on Issuance,” Bank and Corporate Governance Law Reporter Interim Report, January 16, 2014
• Co-author, “Supreme Court Rules that Class Was Not Properly Certified Because Plaintiffs Did Not Establish that Damages Could Be Measured on a Class-wide Basis,” Securities Reform Act Litigation Reporter, Vol. 35 Nos. 1 & 2, April & May 2013

Awards & Accolades

• Recognized by Benchmark Litigation as a "Future Star" in Litigation (2021, 2022)